Highlights of recent faculty research.

Association Between a Population Health Intervention and Hypertension Control

Dugdale DC, Khor S, Liao JM, Flum DR. J Gen Intern Med. 2022 Apr 14. doi: 10.1007/s11606-022-07522-4. Online ahead of print. PMID: 35426007.

Efficacy of a Communication-Priming Intervention on Documented Goals-of-Care Discussions in Hospitalized Patients with Serious Illness: A Randomized Clinical Trial

Lee RY, Kross EK, Downey L, Paul SR, Heywood J, Nielsen EL, Okimoto K, Brumback LC, Merel SE, Engelberg RA, Curtis JR. JAMA Netw Open. 2022 Apr 1;5(4):e225088. doi: 10.1001/jamanetworkopen.2022.5088. PMID: 35363271. Clinical Trial. 

Successes and challenges of implementing a cancer care delivery intervention in community oncology practices: Lessons learned from SWOG S1415CD

Watabayashi KK, Bell-Brown A, Kreizenbeck K, Egan K, Lyman GH, Hershman DL, Arnold KB, Bansal A, Barlow WE, Sullivan SD, Ramsey SD. BMC Health Serv Res. 2022 Apr 1;22(1):432. doi: 10.1186/s12913-022-07835-4. PMID: 35365139. Clinical Trial. 

New insights into the genetic etiology of Alzheimer's disease and related dementias

Bellenguez C, Küçükali F, Jansen IE, … de Rojas I, Bis JC, Yaqub A, … Muchnik C, Mukherjee S, Nacmias B, … EADB; GR @ ACE; DEGESCO; EADI; GERAD; Demgene; FinnGen; ADGC; CHARGE, Farrer LA, Psaty BM, Ghanbari M, … Ruiz A, Ramirez A, Lambert JC. Nat Genet. 2022 Apr;54(4):412-436. doi: 10.1038/s41588-022-01024-z. Epub 2022 Apr 4. PMID: 35379992. 

Variants of Concern Are Overrepresented Among Postvaccination Breakthrough Infections of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) in Washington State

McEwen AE, Cohen S, Bryson-Cahn C, Liu C, Pergam SA, Lynch J, Schippers A, Strand K, Whimbey E, Mani NS, Zelikoff AJ, Makarewicz VA, Brown ER, Bakhash SAM, Baker NR, Castor J, Livingston RJ, Huang ML, Jerome KR, Greninger AL, Roychoudhury P. Clin Infect Dis. 2022 Mar 23;74(6):1089-1092. doi: 10.1093/cid/ciab581. PMID: 34166484; PMCID: PMC8394820.

PROmotion of COvid-19 VA(X)ccination in the Emergency Department-PROCOVAXED: Study protocol for a cluster randomized controlled trial

Rodriguez RM, O'Laughlin K, Eucker SA, Chang AM, Rising KL, Nichol G, Pauley A, Kanzaria H, Gentsch AT, Li C, Duber H, Butler J, Eswaran V, Glidden D. Trials. 2022 Apr 21;23(1):332. doi: 10.1186/s13063-022-06285-x. PMID: 35449064. 

A prospective cohort study to evaluate the incidence of febrile neutropenia in patients receiving pegfilgrastim on-body injector versus other options for prophylaxis of febrile neutropenia: breast cancer subgroup analysis

Mahtani RL, Belani R, Crawford J, Dale D, DeCosta L, Gawade PL, Huynh C, Lawrence T, Lewis S, MacLaughlin WW, Narang M, Rifkin R. Support Care Cancer. 2022 Apr 14:1-10. doi: 10.1007/s00520-022-07025-2. Online ahead of print. PMID: 35426046.

Outcomes for patients with severe chronic neutropenia treated with granulocyte colony-stimulating factor

Dale DC, Bolyard AA, Shannon JA, Connelly JA, Bonilla MA, Newburger PE. Blood Adv. 2022 Apr 27:bloodadvances.2021005684. doi: 10.1182/bloodadvances.2021005684. Online ahead of print. PMID: 35476051. 

Medical and Non-medical Costs of Sickle Cell Disease and Treatments from a US Perspective: A Systematic Review and Landscape Analysis

Baldwin Z, Jiao B, Basu A, Roth J, Bender MA, Elsisi Z, Johnson KM, Cousin E, Ramsey SD, Devine B. Pharmacoecon Open. 2022 Apr 26. doi: 10.1007/s41669-022-00330-w. Online ahead of print. PMID: 35471578.

A landscape analysis and discussion of value of gene therapies for sickle cell disease

Quach D, Jiao B, Basu A, Bender MA, Hankins J, Ramsey S, Devine B. Expert Rev Pharmacoecon Outcomes Res. 2022 Apr 18:1-21. doi: 10.1080/14737167.2022.2060823. Online ahead of print. PMID: 35363602.